Key Points
- Alfred Sandrock sold 11,511 shares of Voyager Therapeutics on April 2 at an average price of $3.87 for ~$44,548, executed under a pre-arranged Rule 10b5-1 plan and reducing his stake to 472,549 shares (a 2.38% decrease); he also made additional sales in February.
- Analyst sentiment is cautiously positive: the consensus rating is a "Moderate Buy" with a consensus target of $16.50, while Truist upgraded to a "strong-buy" and HC Wainwright set a $25 target amid mixed analyst views.
- Recent results and market snapshot: Voyager reported Q results that beat EPS (‑$0.46 vs. estimate ‑$0.54) and revenue ($13.46M vs. $10.49M), has a market cap of ~$236M and a 12‑month trading range of $2.64–$5.55.
Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) CEO Alfred Sandrock sold 11,511 shares of the business's stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $3.87, for a total transaction of $44,547.57. Following the transaction, the chief executive officer directly owned 472,549 shares of the company's stock, valued at approximately $1,828,764.63. This represents a 2.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Alfred Sandrock also recently made the following trade(s):
- On Tuesday, February 24th, Alfred Sandrock sold 14,197 shares of Voyager Therapeutics stock. The shares were sold at an average price of $3.79, for a total value of $53,806.63.
- On Tuesday, February 10th, Alfred Sandrock sold 12,192 shares of Voyager Therapeutics stock. The stock was sold at an average price of $3.78, for a total value of $46,085.76.
Voyager Therapeutics Stock Performance
NASDAQ VYGR opened at $3.96 on Friday. Voyager Therapeutics, Inc. has a twelve month low of $2.64 and a twelve month high of $5.55. The stock has a market capitalization of $236.02 million, a PE ratio of -1.95 and a beta of 1.38. The stock has a 50-day simple moving average of $3.92 and a 200 day simple moving average of $4.18.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its earnings results on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.08. The firm had revenue of $13.46 million during the quarter, compared to the consensus estimate of $10.49 million. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%. As a group, equities research analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on VYGR shares. Truist Financial upgraded shares of Voyager Therapeutics to a "strong-buy" rating in a research note on Wednesday, March 25th. HC Wainwright reiterated a "buy" rating and set a $25.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, March 17th. Finally, Wall Street Zen raised shares of Voyager Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, March 14th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.50.
Check Out Our Latest Report on Voyager Therapeutics
Hedge Funds Weigh In On Voyager Therapeutics
Large investors have recently added to or reduced their stakes in the company. EcoR1 Capital LLC lifted its position in shares of Voyager Therapeutics by 497.2% in the 4th quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company's stock worth $15,731,000 after acquiring an additional 3,332,544 shares during the period. Vanguard Group Inc. grew its holdings in shares of Voyager Therapeutics by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company's stock worth $15,178,000 after purchasing an additional 40,147 shares in the last quarter. Opaleye Management Inc. bought a new stake in shares of Voyager Therapeutics during the fourth quarter valued at approximately $4,704,000. Erste Asset Management GmbH raised its stake in shares of Voyager Therapeutics by 7.0% in the fourth quarter. Erste Asset Management GmbH now owns 1,195,141 shares of the company's stock valued at $4,718,000 after purchasing an additional 78,348 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Voyager Therapeutics by 1.1% in the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company's stock valued at $3,474,000 after purchasing an additional 11,929 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company's stock.
Voyager Therapeutics Company Profile
(
Get Free Report)
Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company's core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.
The firm's pipeline includes several AAV-based candidates in preclinical and early clinical development.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
